Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AUA 2016: Studies Suggest Safety Ahead Of Lipocine's Oral Testosterone PDUFA

Executive Summary

While Lipocine Inc. is at the nail-biting stage of development for its oral testosterone Tlando (LPCN 1021) – awaiting a US FDA approval decision – urologists continue to study testosterone therapy to determine whether treatment of hypogonadal men is safe with appropriate monitoring.

Advertisement

Related Content

FDA imposes heart attack, stroke warnings on testosterones
Lipocine SOARS on oral testosterone data despite FDA concerns

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register